PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology ...

In a new study, Chinese researchers have discovered the previously unrecognized role of alternative splicing of the DOC2A gene in schizophrenia. The research was conducted by scientists led by LI Ming ...

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages ...

AlphaGenome is a DNA sequence model that advances regulatory variant-effect prediction to understand genome function.

Antal and Yeo, who also are members of UCSD’s Moores Cancer Center, say the key to targeting triple-negative breast cancer, or TNBC, is managing a protein called poly (U)-binding splicing factor 60, ...

Skyhawk Therapeutics announces interim results in patients from phase 1 clinical trial as a treatment for Huntington’s disease: Waltham, Massachusetts Thursday, January 29, 2026 ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have improved in recent years, approximately 30% of patients relapse following ...

A new AI model by Google DeepMind can decipher DNA and predict mutations, opening new doors for disease research. View on ...

The tool helps scientists understand how single-letter mutations and distant DNA regions influence gene activity, shaping ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...